Close Menu

Breast Cancer

News and reporting on breast cancer.

Bernard Fisher Dies

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

The group will validate Miraca's prototype extracellular vesicle isolation tool and antibody reagents using blood samples from breast and pancreatic patients.

Data from more than 11,800 women with breast cancer suggested unselected BRCA1, BRCA2, and PALB2 testing is cost-effective for UK and US payors and societies.

The WGS analysis placed the triple-negative breast cancers into three groups, each of which had different treatment responses and prognoses.

The new analysis has confirmed earlier evidence that patients with high Oncotype DX risk scores appear to benefit significantly from added chemotherapy.

The company will collaborate the Parker Institute for Cancer Immunotherapy, Institut Gustave Roussy in France, and the University Health Network in Toronto, Canada.

The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.

The company will work with the Genome Institute of Singapore to create a test for breast cancer recurrence prediction using its circulating tumor cell platform.

In PLOS this week: deletion in NME5 linked to primary ciliary dyskinesia in Alaskan Malamutes, study of rabies virus movement in Ontario, and more.

The San Diego-based firm has developed a new extracellular RNA sequencing method that it believes could be used for cancer diagnostics.

Pages

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.